For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...